Skip to main content
UFPT logo

UFPT · Ufp Technologies Inc

Track UFPT — free
Market Cap
$2.15B
Shares
7.75M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$277.89 Open$281.34 Day$275.51–282.16 52W close$185.28–334.84 Avg vol 30d155K Short int1.1M · 13.6% float · 8.9d Short vol67% Last earningsAug 4, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 7 wks
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$631.64M
Trailing 12 months
Net income (TTM)
$72.30M
Trailing 12 months
Revenue growth YoY
+15.1%
Year over year
Operating margin
15.3%
Trailing 12 months
P / E (TTM)
29.9
Trailing earnings · reciprocal yield 3.3%
FCF yield
TTM · current market cap
Return on invested capital
13.8%
Trailing 12 months
Net cash
−$108.26M
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
+38.0%
Trailing year
Short interest
13.6%
Latest settlement · 8.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg −1%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 62%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −13%
trailing
6-month return +45%
trailing
YTD return +25%
this year
Relative strength +28%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $281 › 200d $239 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +42 funds added
Insider flow Distributing
Net -$12.6M over 90 days · 100% sells
Short interest Falling
13.60% of float · ▼ -1.8% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
280 holders — mid 3-yr range
Squeeze score 75
high risk · 0–100
Fundamentals
Strong
Revenue growth +20%
Y/Y
Gross margin 28%
contracting
EPS growth +15%
Y/Y
Free cash flow $82.2M
Valuation P/E 30
in line
Buyback $10.0M
authorized
Balance sheet $115.2M
net debt
Quant / Vol
risk profile
High
Volatility 50%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
−1% Neutral
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
62% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $281 › 200d $239 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +42 funds added
Insider flow Distributing
Net -$12.6M over 90 days · 100% sells
Short interest Falling
13.60% of float · ▼ -1.8% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
280 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $185 Now $278 · 62% Range high $335
vs 200-day avg +16% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
UFPT
Ufp Technologies Inc
this stock
$2.15B +25.2% +19.5% 30.0 13.6%
ABT
Abbott Laboratories
$177.58B -18.6% +5.7% 28.6 1.3%
MDT
Medtronic plc
$116.35B -5.3% +8.4% 22.4 0.9%
SYK
Stryker Corp
$105.70B -21.6% +11.2% 28.6 2.0%
BSX
Boston Scientific Corp
$62.29B -54.9% +12.5% 17.4 3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
280
% held
123.0%
Net QoQ
+741.2K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
294
View
Short & Settlement
Short Interest Falling
Shares short
1.1M
Days to cover
8.9d
Change
-19.8K sh
View
Short Volume
Short vol %
67%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$322
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
47.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$12.6M
Buyers / Sellers
0 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$602.8M
Net income (FY)
$68.3M
EPS diluted
$8.75
View
Buybacks
Authorized
$10.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 24, 2026
This year
16
View
Proposed Sales
Value
$2.1M
Shares
7.0K
Filed
Aug 25, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2026
View

Performance

5D 20D 120D MTD YTD
UFPT -3.0% -13.1% +45.5% -6.7% +25.2%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -1.9% -11.4% +27.6% -6.4% +13.1%

Capital returns

Buyback program · as of Jun 16, 2015
Authorized
$10.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 914156 CUSIP 902673102 13F (30d) 59 filings 59 filers Visit website